The safety data used by regulatory bodies like the FDA and EPA often comes from the very companies seeking approval for their products, raising questions about objectivity. Carey shares a troubling example involving Monsanto and glyphosate, where the company influenced the interpretation of cancer-related data, highlighting a systemic issue in how safety studies are conducted and evaluated. This discussion underscores the need for independent research funding to ensure public safety is prioritized over corporate interests.
